Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on EquityReturn on Sales

Prelude Therapeutics (PRLD) Net Margin (2024 - 2025)

Historic Net Margin for Prelude Therapeutics (PRLD) over the last 2 years, with Q3 2025 value amounting to 314.12%.

  • Prelude Therapeutics' Net Margin rose 8317400.0% to 314.12% in Q3 2025 from the same period last year, while for Sep 2025 it was 516.66%, marking a year-over-year change of. This contributed to the annual value of 1995.91% for FY2024, which is N/A changed from last year.
  • Per Prelude Therapeutics' latest filing, its Net Margin stood at 314.12% for Q3 2025, which was up 8317400.0% from 845.78% recorded in Q4 2024.
  • Prelude Therapeutics' 5-year Net Margin high stood at 314.12% for Q3 2025, and its period low was 1145.87% during Q3 2024.